AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03473002 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Sodium Chloride
Study NCT03473002 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SeVRSV Vaccine
Description: Recombinant Sendai virus vectored respiratory syncytial virus (SeVRSV) vaccine. SeVRSV is a replication-competent Sendai virus that carries the RSV F gene produced by reverse genetics technology.
Study NCT04545359 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham neurofeedback
Description: Twelve 21-minute sessions (minimum of 1 session and maximum of 3 sessions per week) of an auditory sham neurofeedback with the Melomind device developed by myBrain Technologies (France). Sham feedback is based on the real feedback of the participants in the Experimental arm. Recording of felt relaxation, perceived stress level, anxiety level pre-post sessions.~Electrophysiological: Recording of EEG signals on 32 electrodes every two sessions.
Study NCT04350346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Motilitone
Description: 1. Ingredients and content: corydalis tuber, pharbitis seed 50% EtOH extracts 30mg~2. Dosage method: Usually, adults take 1 tablet 3 times a day orally before meals.~3. Pharmacological action:~   * It stimulates 5-HT4 receptor as a gastrointestinal motility accelerator to increase acetylcholine secretion and contract smooth muscle.~     * Stimulates stomach smooth muscle contraction by suppressing the effect of dopamine on acetylcholine secretion by inhibiting D2 receptor ③ It shows a pharmacological action that stimulates gastrointestinal movement by acting in combination with 5-HT1A / B receptor.
Study NCT04350346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gasmotin
Description: 1. Ingredient and content: mosapride citrate dihydrate 5.29mg (5mg as active ingredient)~2. Dosage method: Usually, an adult is orally administered 1 tablet 3 times a day before meals.~3. Pharmacological action: mosapride is a selective serotonin-4 (5-HT4) receptor agonist with gastrointestinal stimulating activity, contracting smooth muscle
Study NCT02779712 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischaemic conditioning
Description: 1 dose (=4 cycles) of intermittent upper limb ischaemia (1 cycle = 5minutes inflation to 20mmHg above systolic BP, 5 minutes deflation). Dose escalation: (i) Recruits 1-20 receive this cycle once (ii) Recruits 21-40 receive a second dose of 4-cycles one hour after the first. (iii) Recruits 41-60 receive further dosing, twice daily until day 4.
Study NCT02779712 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: 4 cycles of intermittent sham procedure (1 cycle = 5 minutes inflation to 30 mmHg, 5 minutes deflation), matching the dose escalation described in the intervention
Study NCT04553406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPR720
Description: Capsules for oral administration
Study NCT04553406 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules for oral administration
Study NCT04553406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Open-label Standard of Care
Description: Standard of Care regimen is at the Investigator's discretion; recommended 2-drug or 3-drug SOC, consisting of either:~* Clarithromycin 500-1000 mg, plus ethambutol hydrochloride (HCl) 15 mg/kg orally once daily or~* Azithromycin 250-500 mg plus ethambutol HCl 15 mg/kg orally once daily.~Optional rifampin 600 mg or rifabutin 300 mg orally once daily may be added to the SOC regimen for up to 28 days.
Study NCT03535987 — intervention group
Intervention type: DEVICE
Intervention: myocardial PET imaging
Description: using myocardial PET imaging as a means to assess cardiovascular risk in men with prostate cancer planned for androgen-deprivation therapy with external beam radiation therapy
Study NCT02409797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flexion-Distraction (non-thrust) spinal manipulation
Description: Enrolled participants will receive chiropractic care over a 2-week period. Chiropractic care includes standard therapies for back pain. A doctor of chiropractic determines the therapeutic approach and treatment frequency based upon a participant's clinical presentation. If provided, treatments will include low-velocity (non-thrust) spinal manipulation using the Flexion-Distraction procedure. Recommendations for exercise, lifestyle modifications, or other therapies may also be provided.
Study NCT01528293 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ActiVAC System
Description: The ActiV.A.C. System will be applied in a customary manner per manufacturer's recommendations. Acticoat Flex 7™ will be applied as contact layer on the wound surface. Open cell foam is then applied over the top of the Acticoat Flex 7™. Adherent transparent occlusive material will be applied over the open cell foam. The tubing is then attached after cutting a small aperture through the occlusive material. Negative pressure will be set at 125mmHg on continuous suction. Sponge and canister will be replaced 2 time a week.
Study NCT01528293 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compression therapy
Description: Compression Therapy Profore™ multi-layered compression bandaging system will be utilized. This includes the application of a contact layer dressing using Acticoat Flex 7™. The compression bandage will be applied per manufacturer's recommendations.
Study NCT01528293 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Compression therapy
Description: Compression Therapy Profore™ multi-layered compression bandaging system will be utilized. This includes the application of a contact layer dressing using Acticoat Flex 7™. The compression bandage will be applied per manufacturer's recommendations.
Study NCT01675739 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short message service of mobile phone (SMS)
Description: In SMS group, patients took 1st dose polyethylene glycol (PEG) 2L at 6-8pm the day before colonoscopy and then start to take 2nd dose PEG 2L after receiving Short message service of mobile phone (SMS) 6hours before afternoon colonoscopy.
Study NCT01675739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyethylene glycol (PEG)
Description: No-SMS group took 1st 2L of PEG solution at 6-8 PM on the day before colonoscopy and started drinking the 2nd 2L PEG at about 6hours before the day of the colonoscopy.~SMS group took 1st 2L PEG as same manner of No-SMS group and then started drinking the 2nd 2L PEG at about 6hours before the day of the colonoscopy after receiving scheduled SMS
Study NCT01675739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polyethylene glycol (PEG)
Description: No-SMS group took 1st 2L of PEG solution at 6-8 PM on the day before colonoscopy and started drinking the 2nd 2L PEG at about 6hours before the day of the colonoscopy.~SMS group took 1st 2L PEG as same manner of No-SMS group and then started drinking the 2nd 2L PEG at about 6hours before the day of the colonoscopy after receiving scheduled SMS
Study NCT03540160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg Serlopitant Tablets
Description: Serlopitant Tablets
Study NCT03505008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Route of Administration: Oral
Study NCT02637128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine (AL)
Description: Dispersible formulation of artemether-lumefantrine (Coartem-D™; 20mg artemether/120mg lumefantrine per tablet, Novartis, Switzerland) administered twice a day for 3 days according to manufacturer recommended dosing for weight
Study NCT02637128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artesunate-amodiaquine (ASAQ)
Description: Co-formulated artesunate-amodiaquine (25mg artesunate/67.5mg amodiaquine and 50mg artesunate/135mg amodiaquine tablets) administered once a day for 3 days, according to manufacturer recommended dosing for weight
Study NCT01234818 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mirena (LNG-IUS)
Description: * General Name/Brand name: Mirena - Bayer ② Active ingredient: levonorgestrel 52mg ③ Description: Mirena is a hormone-releasing T-shaped intrauterine system. A removal thread is attached to a loop at the end of the vertical stem of the T-body.
Study NCT01920555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Dose of Ketamine will be 0.1 mg/kg - one single infusion
Study NCT01920555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Dose of Ketamine will be 0.2 mg/kg - one single infusion
Study NCT03090217 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care (SC)
Description: 1) daily vaginal dilator therapy (10 to 15 minutes) and 2) usual care management.
Study NCT03748264 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: In the standard of care or the control condition, participants will receive the sites therapy initiation standard of care for setting up and educating the participants on their Obstructive Sleep Apnea, mask, and device information. This group will use a wireless modem that is attached to the PAP device and uploads adherence and other therapy information daily to a secured database (Encore Anywhere). With this method, therapy information is not directly available to the participant but will continuously be available to site staff personnel.
Study NCT03748264 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DreamMapper Application
Description: The DreamMapper application condition will receive the site's therapy initiation standard of care and will also download the DreamMapper application on their iPhone or Android smart phone. Therapy information and educational material will be available continuously to the participant with DreamMapper through the application. Study personnel will have access to adherence and therapy information continuously.
Study NCT03748264 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DreamMapper Application with Therapist Assist
Description: The DreamMapper with Therapist Assist will review the Therapist Assist automated educational material on Obstructive Sleep Apnea, their Philips Respironics mask and DreamMapper. These participants will download the DreamMapper application onto their iPhone or Android smart phone. Therapy information and educational material will be available continuously to the participant with DreamMapper. Study personnel will have access to adherence and therapy information continuously.
Study NCT04261920 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Huangqi Guizhi Wuwu decoction
Description: The experimental group took Huangqi Guizhi Wuwu decoction twice a day, infused with warm water. Consistently used during patients receiving XELOX5 adjuvant chemotherapy for at least 12 weeks (every 3 week is a cycle, 4 cycles).~The control group took placebo twice a day, infused with warm water. Consistently used during patients receiving XELOX5 adjuvant chemotherapy for at least 12 weeks (every 3 week is a cycle, 4 cycles).
Study NCT04261920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huangqi Guizhi Wuwu decoction
Description: The experimental group took Huangqi Guizhi Wuwu decoction twice a day, infused with warm water. Consistently used during patients receiving XELOX5 adjuvant chemotherapy for at least 12 weeks (every 3 week is a cycle, 4 cycles).~The control group took placebo twice a day, infused with warm water. Consistently used during patients receiving XELOX5 adjuvant chemotherapy for at least 12 weeks (every 3 week is a cycle, 4 cycles).
Study NCT04572542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab One course will last 21 days.Given once every 3 weeks at a dose of 200 mg
Study NCT04572542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: Apatinib One course will last 21 days.Oral administration at a dose of 250 mg everyday
Study NCT04572542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: nab-paclitaxel One course will last 21 days。Given twice every 3 weeks at a dose of 125 mg/m2
Study NCT04089176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: carbetocin 100 mcg + RLS solution 10 ml injected directly into the vein over 2 min
Study NCT04089176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxytocin
Description: oxytocin 20 IU diluted in 1000 ml of RLS solution administered intravenously at rate 120 ml/hr x 8 hr
Study NCT00664521 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered as an intravenous infusion at a dose of 1000 mg at Weeks 1 and 3.
Study NCT00664521 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: Rituximab will be administered as an intravenous infusion at a dose of 1000 mg at Weeks 1 and 3.
Study NCT00664521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept
Description: Atacicept will be administered at a dose of 150 mg subcutaneously once a week from Week 7 to 32.
Study NCT00664521 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matched to atacicept
Description: Placebo matched to atacicept will be administered subcutaneously once a week from Week 7 to 32.
Study NCT03818997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKN-01
Description: Patient will receive DKN-01 300 mg IV every 2 weeks
Study NCT01920555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Dose of Ketamine will be 0.5 mg/kg - one single infusion
Study NCT01920555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Dose of Ketamine will be 1.0 mg/kg - one single infusion
Study NCT01920555 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Midazolam
Description: Dose of Midazolam (active placebo) will be 0.045 mg/kg - one single infusion
Study NCT01123239 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coached Care
Description: Coached Care pairs patients with linguistically and ethnically matched peer coaches, who themselves have diabetes, and have been trained to meet with patients immediately before each of their regularly scheduled medical visits to encourage active involvement in information seeking and decision-making. Using a decision tree algorithm, they help patients identify relevant questions about symptoms, barriers to self-management and treatment options to discuss with doctor. They encourage mutual decision-making about tailoring the patient's medication regimen, diet and physical activities and work with the patients to overcome barriers to communication with their doctor. After the medical visit, the coach and patient review any treatment decisions and goals for self-care.
Study NCT01123239 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Diabetes Education
Description: Patients randomized to the control group will receive 20 minutes of standardized diabetes education delivered by staff research assistants. Education materials have been adapted from materials developed by the American Diabetes Association. The content of these materials includes information about the causes and complications of diabetes, as well as ways to reduce complication risks. Patients in the control arm will receive 20 minutes of standardized diabetes education before each visit
Study NCT01323842 — intervention group
Intervention type: PROCEDURE
Intervention: EDTU
Description: bedside ultrasound imaging by the treating emergency physician
Study NCT03415100 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-NK cells targeting NKG2D ligands
Description: The infusion of CAR-NK cells will be performed in the Third Affiliated Hospital of Guangzhou Medical University. Following infusion of CAR-NK cells, interleukin-2 (IL-2) will be injected subcutaneously into some patients to support the in vivo survival of CAR-NK cells. The subject will be observed for any side effects during this time and all the adverse events will be recorded.
Study NCT04026581 — intervention group
Intervention type: BEHAVIORAL
Intervention: Speech generating device (SGD) evaluation including BCI access
Description: At the initial evaluation the participants will review the full range of AAC options and speech generating devices (SGDs) and complete a speech and language evaluation. The second evaluation date will involve a trial of SGDs matched to the participant's assessment results. The third visit is the trial of an AAC system with BCI access. Should the dry electrode headgear for BCI access prove ineffective, then the gel electrode cap will be offered to the participant for trial. At the end of the third visit, the evaluation results will be discussed with participant and family, and they will be asked to select the preferred SGD.
Study NCT04026581 — intervention group
Intervention type: BEHAVIORAL
Intervention: Training and treatment
Description: Participants receive training on the selected SGD followed by monthly treatment sessions from the SLP who monitors performance. In some cases the participants' SGD will be an AAC system with BCI access. In this case training will also include an identified system support person. Use of the SGD is monitored on a monthly basis through home visits and/or tele-practice sessions, when requested. Technical support for the SGD is provided on an as needed basis or when requested by the participant or support person.
Study NCT02474680 — intervention group
Intervention type: GENETIC
Intervention: Pharmacogenetic testing
Description: Psychotropic genotyping panel
Study NCT04224883 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuously feeding
Description: Daily amount of feeding were continuously pumped for 24 hours. EN preparation pumping scheme was as follows: The initial pumping speed was average pumping volume of total enteral nutrition in one day, and gastric residual volumes is checked every 4 hours. If it is not tolerable, the speed of the pumping is reduced by half on the original speed. GRV\<200mL were considered markers of good tolerance.Feeding intolerance was defined as GRV>200 mL. If GRV>500mL, EN was stopped and reassessed after 4 hours.
Study NCT04224883 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 16-hours feeding
Description: Daily amount of feeding were continuously pumped for 16 hours.EN preparation pumping scheme was as follows: The initial pumping speed was average pumping volume of total enteral nutrition in one day, and gastric residual volumes is checked every 4 hours.If it is not tolerable, the speed of the pumping is reduced by half on the original speed. GRV\<200 mL were considered markers of good tolerance. Feeding intolerance was defined as GRV>200 mL. If GRV>500mL, EN was stopped and reassessed after 4 hours.
Study NCT04224883 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intermittent feeding
Description: Daily amount of feeding were divided into four meals, each meal are pumped within 60mins or 120mins through stomach tube. EN preparation pumping scheme was as follows: If the volume of each meal is less than or equal to 250ml(≤250ml), pump in within 60min, if volume is greater than 250ml(>250ml), pump in within 120min and gastric residual volumes is checked before each intermittent feeding. If it can be tolerated, the velocity of the pumping can be increased by half of the original speed.If it is not tolerable, the speed of the pumping is reduced by half on the original speed. GRV\<200 mL were considered markers of good tolerance. Feeding intolerance was defined as GRV>200 mL. If GRV>500mL, EN was stopped and reassessed after 4 hours.
Study NCT01703286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching Glimepiride
Study NCT01703286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: given once daily for 28 days
Study NCT01703286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo matching Linagliptin
Study NCT01703286 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching Linagliptin
Study NCT01703286 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching Glimepiride
Study NCT04766372 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behaviour change
Description: Using needs supportive, self-determination theory-based, components to improve the physical activity behaviours of adolescent girls.
Study NCT03977454 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nerve Block
Description: Nerve blocks (QLB/LFCNB) to be placed preoperatively with DEX/MPA, per standard of care of anesthesia block service.~1. QLB: 40ml 0.2% ropivacaine with 5 mg DEX/ 40 mg MPA~2. LFCNB: 20ml 0.2% ropivacaine with 5 mg DEX/ 40 mg MPA
Study NCT03977454 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periarticular Injection (PAI)
Description: Intraoperatively, the surgeon will perform PAI per standard of care with the medications:~1. 60 ml 0.2% ropivacaine and 10 mg DEX/ 80 mg MPA
Study NCT03977454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 60 ml 0.2% ropivacaine
Study NCT03977454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 60 ml 0.2% ropivacaine
Study NCT03977454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dex
Description: 10 mg DEX/ 80 mg MPA
Study NCT00963677 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nasotracheal Intubation through seeing optical stylet (SOS)
Description: Nasotracheal intubation using seeing optical stylet in the patients with the anticipated difficult intubation. Arm 1:routine anesthesia induction,0.1mg/kg midazolam, 3-8mcg/kg fentanyl, 0.08-0.15mg/kg vecuronium and 0.3mg/kg etomidate, Nasotracheal intubation with seeing optical shikani; Arms 2: Sevoflurane combined with oxyge, 0.3mg/kg Etomidate and 1-2mg/kg succinylcholine for intubation, nasotracheal intubation with seeing optical shikani